MRK Merck & Co Inc

Price (delayed)

$77.54

Market cap

$196.34B

P/E Ratio

27.89

Dividend/share

$2.56

EPS

$2.78

Enterprise value

$220.61B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
Merck's equity has increased by 6% from the previous quarter and by 2.8% YoY
The P/E is 32% lower than the 5-year quarterly average of 41.3 but 19% higher than the last 4 quarters average of 23.5
The net income has declined by 31% year-on-year
The EPS has contracted by 30% YoY

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$196.34B
Enterprise value
$220.61B
Valuations
Price to earnings (P/E)
27.89
Price to book (P/B)
7.28
Price to sales (P/S)
4.09
EV/EBIT
26.28
EV/EBITDA
18.19
EV/Sales
4.59
Earnings
Revenue
$48.02B
EBIT
$8.39B
EBITDA
$12.13B
Free cash flow
$6.51B
Per share
EPS
$2.78
Free cash flow per share
$2.57
Book value per share
$10.65
Revenue per share
$18.98
TBVPS
$22.22
Balance sheet
Total assets
$90.85B
Total liabilities
$63.81B
Debt
$31.25B
Equity
$26.95B
Working capital
$548M
Liquidity
Debt to equity
1.16
Current ratio
1.02
Quick ratio
0.58
Net debt/EBITDA
2
Margins
EBITDA margin
25.3%
Gross margin
67%
Net margin
14.6%
Operating margin
14.6%
Efficiency
Return on assets
7.7%
Return on equity
25.8%
Return on invested capital
15.8%
Return on capital employed
13%
Return on sales
17.5%
Dividend
Dividend yield
3.3%
DPS
$2.56
Payout ratio
92.1%

MRK stock price

How has the Merck stock price performed over time
Intraday
1.32%
1 week
-0.62%
1 month
2.59%
1 year
-0.67%
YTD
-5.21%
QTD
-0.3%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$48.02B
Gross profit
$32.18B
Operating income
$7.01B
Net income
$7.03B
Gross margin
67%
Net margin
14.6%
Merck's operating margin has decreased by 43% YoY and by 12% QoQ
Merck's operating income has decreased by 43% YoY and by 11% from the previous quarter
MRK's net margin is down by 31% year-on-year
The net income has declined by 31% year-on-year

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
27.89
P/B
7.28
P/S
4.09
EV/EBIT
26.28
EV/EBITDA
18.19
EV/Sales
4.59
The P/E is 32% lower than the 5-year quarterly average of 41.3 but 19% higher than the last 4 quarters average of 23.5
The EPS has contracted by 30% YoY
The price to book (P/B) is 17% higher than the 5-year quarterly average of 6.2
Merck's equity has increased by 6% from the previous quarter and by 2.8% YoY
MRK's P/S is 4.9% below its 5-year quarterly average of 4.3 and 2.6% below its last 4 quarters average of 4.2

Efficiency

How efficient is Merck business performance
The ROIC fell by 38% YoY and by 8% QoQ
The company's return on assets fell by 36% YoY and by 2.5% QoQ
Merck's ROE has decreased by 32% YoY
The ROS has contracted by 31% YoY and by 4.4% from the previous quarter

Dividends

What is MRK's dividend history
DPS
$2.56
Dividend yield
3.3%
Payout ratio
92.1%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 42% more than the total liabilities
MRK's quick ratio is down by 12% year-on-year
Merck's total liabilities has increased by 9% YoY but it has decreased by 3.6% QoQ
MRK's debt is 16% greater than its equity
MRK's debt is up by 12% year-on-year
The debt to equity has grown by 8% YoY but it has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.